VANCOUVER, Aug. 6 /CNW/ - Burcon NutraScience Corporation (TSX -BU)
("Burcon" or the "Corporation") announced today that it has engaged Mr. Sven
Olsson of Goeppingen, Germany, to perform investor relations services by
assisting Burcon with communicating its corporate message to financial markets
in Europe. Mr. Olsson has been working on behalf of Burcon over the last six
years when he was with AXINO AG, a Stuttgart based investor relations firm.
Burcon will continue to use the services of AXINO AG for its general investor
relations activities in Europe.
Mr. Olsson is an accomplished professional with over fifteen years in the
communications business of which he dedicated the last eight years to the
North American investment and finance industry. Since 2001, Mr. Olsson has
held the position of Director of Media and Corporate Communications at AXINO
AG, a European consulting firm specializing in communications for companies in
the resource sector. In his role, Mr. Olsson was responsible for investor
relations in Europe for numerous major and micro cap resource-based companies
in all phases of development. His network of contacts within the financial
communities as well as media extends across Europe and North America.
The Investor Relations Service Agreement (the "Agreement") has a term of
24 months. The Agreement is also terminable upon 30 days notice by either
party. The Corporation will pay Mr. Olsson (euro)750 per day for attendance at
investor meetings in Europe and has also granted him an option to purchase up
to a total of 15,000 Common shares in the capital of Burcon at an exercise
price of $6.10 per share. The option will have a term of five years from the
date of grant and will vest as to 33 1/3% on the date that is 8, 16 and 24
months from the date of grant, respectively.
About Burcon NutraScience
Burcon is a leader in nutrition, health and wellness in the field of
functional, renewable plant proteins. Since 1999, Burcon has developed a
portfolio of composition, application, and process patents originating from
our core protein extraction and purification technology. We are developing the
world's first commercial canola proteins, Puratein(R) and Supertein(TM) with
unique functional and nutritional attributes, and CLARISOY(TM), a
revolutionary soy protein isolate which is 100% soluble and completely
transparent in acidic solutions. Our team of highly specialized scientists and
engineers work from our own research facility to develop and optimize
environmentally sound technologies. To-date, our patent portfolio consists of
86 issued patents in various countries, including 8 issued U.S. patents, and
in excess of 200 additional pending patent applications, 61 of which are U.S.
ON BEHALF OF THE BOARD OF DIRECTORS
"Johann F. Tergesen"
Johann F. Tergesen
President and Chief Operating Officer
Burcon NutraScience Corporation is a publicly listed on the Toronto Stock
Exchange under the symbol "BU". For more information on Burcon, visit
This press release contains forward-looking statements that involve risks
and uncertainties. These forward-looking statements relate to, among other
things, the Corporation's, plans and timing for the introduction or
enhancement of our products, statements about future market conditions, supply
and demand conditions, and other expectations, intentions and plans contained
in this press release that are not historical fact. Our expectations regarding
the prospect for future success depend upon our ability to develop and sell
products, which we do not produce today and cannot be sold without further
research and development. When used in this press release, the words "goal",
"intend", "believes", "potential", "expected", "anticipates", "will be", and
similar expressions, generally identify forward-looking statements. These
statements reflect our current expectations. They are subject to a number of
risks and uncertainties. In light of the many risks and uncertainties
surrounding the development of a source of protein from canola meal, you
should understand that we cannot assure you that the forward looking
statements contained in this press release will be realized.
For further information:
For further information: Jade Cheng, Chief Financial Officer, Burcon
NutraScience Corporation, (604) 733-0896, (888) 408-7960 toll-free,
firstname.lastname@example.org, www.burcon.ca; AXINO AG: Wolfgang Seybold, Investor
Relations Europe, AXINO AG, Konigstrasse 26, 70173 Stuttgart, Germany, Tel.
+49-711-25 35 92-40, Fax +49-711-25 35 92-55, email@example.com,